Hemogenyx Pharmaceuticals PLC CBR Expanded to Treatment of Cancer (6697U)
2023年11月27日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMHEMO
RNS Number : 6697U
Hemogenyx Pharmaceuticals PLC
27 November 2023
27 November 2023
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
CBR Expanded to Treatment of Cancer
Chimeric Bait Receptor-programmed macrophages show promise for
treatment of Non-Hodgkin Lymphoma
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments for blood diseases,
is pleased to announce that its Chimeric Bait Receptor ("CBR")
platform can potentially be used in the treatment of cancers, in
addition to the viral diseases extensively reported by the Company
to date.
The Company has demonstrated that human macrophages, a type of
immune cells, programmed with a purpose designed CBR, were able to
eliminate Non-Hodgkin Lymphoma ("NHL") derived cells with high
efficiency in vitro. This result suggests that the Company may be
able to develop an efficient treatment for people suffering from
relapsed and/or refractory stage III/IV metastasized NHL. In
addition, based on data derived from its testing of CBR in
connection with NHL, the Company has reason to believe that the
newly designed CBR construct can be adapted to target several solid
tumours such as epithelial ovarian cancer as well as certain
carcinomas.
The Company has been able to speed up its R&D efforts
dramatically by using Artificial Intelligence ("AI") based protein
structure/interaction simulations and in-house synthesis of
messenger RNA ("mRNA"). AI tools allow the Company's scientists to
triage variants of CBR constructs rapidly in order to select those
with the greatest likelihood of success, while in-house mRNA
synthesis facilitates the building of CBR constructs in a matter of
just days.
Moreover, the Company has previously reported that it is testing
CBR against live infectious SARS-Cov-2, the virus causing COVID-19.
The Company has received preliminary results of tests of CBR
against this live infectious virus. The results show that human
macrophage cells programmed with CBR against SARS-CoV-2 are
effective in in vitro experiments. These tests are being conducted
by an external team of scientists in a biological level three
("BSL-3") facility. Additional work will be conducted to further
optimize the method of application of cells programmed with CBR, as
well as to obtain results in vivo (i.e., in a live animal
model).
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented: "This is an exciting breakthrough in
proving the versatility of our CBR platform, greatly widening its
potential use against cancers, in addition to the original pursuit
of combatting viral infections. We are extremely pleased to see
that CBR can potentially be used to develop new treatments for
cancers such as NHL, as well as potentially for solid tumours,
which are a significant challenge for existing therapies. We have
also made meaningful advances in proving CBR's potential viability
in treating COVID-19 and other viruses. We are hugely encouraged by
these recent developments, and I am proud of Hemogenyx
Pharmaceuticals' team of scientists who achieved this leap
forward."
About NHL
NHL is a subtype of cancers called lymphomas that develop in the
lymph system. NHL develops predominantly in adults, although
children can also suffer from this disease. NHL is the 11(th) most
common cancer in humans, with roughly 540,000 new cases diagnosed
globally and an estimated 260,000 deaths per year. In the US, NHL
is estimated to affect 80,550 people, with 20,180 deaths resulting
from this cancer in 2023 alone. The successful development of a new
therapy for NHL would have a major impact on treatment and survival
rates for the disease.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been inside information for the purposes of Article 7 of Regulation
No 596/2014 (as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018) until the release of this
announcement.
The person responsible for arranging for the release of this
announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr
Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New
York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to treat blood and
autoimmune disease and to bring the curative power of bone marrow
transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary
product candidates, as well as a platform technology that it uses
as an engine for novel product development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCLQLFLXFLFFBD
(END) Dow Jones Newswires
November 27, 2023 02:00 ET (07:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 8 2024 まで 9 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 9 2023 まで 9 2024